These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 10577980)
1. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Fries JF Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I86-9. PubMed ID: 10577980 [No Abstract] [Full Text] [Related]
2. The economics of treatment in early rheumatoid arthritis. Bansback N; Marra CA; Finckh A; Anis A Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Modena V; Bianchi G; Roccatello D Autoimmun Rev; 2013 Jun; 12(8):835-8. PubMed ID: 23219766 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606 [No Abstract] [Full Text] [Related]
6. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149 [TBL] [Abstract][Full Text] [Related]
9. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622 [TBL] [Abstract][Full Text] [Related]
10. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia]. Mora C; González A; Díaz J; Quintana G Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomics of long-term treatment of rheumatoid arthritis. Blumenauer B; Coyle D; Tugwell P Expert Opin Pharmacother; 2002 Apr; 3(4):417-22. PubMed ID: 11934345 [TBL] [Abstract][Full Text] [Related]